Idelalisib Recruiting Phase 2 Trials for Refractory Nodal Marginal Zone Lymphoma / Recurrent Nodal Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Small Lymphocytic Lymphoma / Refractory Splenic Marginal Zone Lymphoma / Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / chronic, recurrent Lymphocytic Leukemia / Recurrent Grade 3 Follicular Lymphoma / Refractory Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Waldenström's Macroglobulinemia (WM) / Recurrent Marginal Zone Lymphoma / Chronic Lymphocytic Leukemia (CLL) - Refractory / Richter's Syndrome / Recurrent Splenic Marginal Zone Lymphoma Treatment